Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MGD020

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and HIV-1 envelope glycoprotein gp41 subunit · developed by MacroGenics

Phase 1 Most advanced trial (none active)
MGNX Developer
1 Registered trials

What is MGD020?

MGD020 is a bispecific DART molecule that binds CD3 and the gp41 subunit of the HIV-1 envelope. It is being studied in human immunodeficiency virus type 1 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
CD3 (CD3E), HIV-1 envelope glycoprotein gp41 subunit
Mechanism
Immune activation, directed at CD3 (CD3E) and HIV-1 envelope glycoprotein gp41 subunit
Therapy area
Infectious disease
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05261191 Phase 1 Human Immunodeficiency Virus I Infection Completed MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Human Immunodeficiency Virus I InfectionHuman Immunodeficiency Virus Type 1Immunodeficiency Virus Type 1, Human

Other drugs acting on CD3E

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind MGD020

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.